Home > Boards > US OTC > Delisted > Cannabis Science Inc. (fka CBIS)
Followed By 181
Posts 39049
Boards Moderated 3
Alias Born 09/21/2010

Friday, April 15, 2011 4:48:13 PM

Re: platero post# 22698

Post# of 129039
Business Development

Our business and product development will follow two parallel paths. We will create cannabis pharmaceuticals with and without psychoactive properties. Both of these lines will have numerous proven health benefits for treating autism, blood pressure, cancer and cancer side effects, along with other illnesses, including for general health maintenance.

We are positioned to pursue the development of phytocannabinoid-based pharmaceutical grade products. The endocannabinoid system normally regulates blood pressure through its capacity to dilate blood vessels and reduce adrenergic stimuli. Additionally, there is a developing body of evidence that shows both the tumor killing properties of endo- and phyto- cannabinoids, and their ability to inhibit metastasis in a variety of cancers.

The Company is working to navigate the regulatory framework for its phytocannabinoid science towards developing cannabis-based therapeutics that will holistically promote health by restoring biochemical balance. By adhering to underlying scientific principles, the Company will manipulate all-pervasive phytocannabinoid processes to target a variety of disparate illnesses.

Cannabis Science is also positioning to explore insights that indicate an intrinsic link between novel cancer and HIV technologies and the cannabinoid system; with the goal of demonstrating that our pharmaceuticals will enhance biochemical markers that are indicative of a successful HIV therapy based on recent paradigm breaking discoveries.

The Company is currently focused on FDA approval of its first medical cannabis product targeted for veterans. Many veterans are already using herbal cannabis to self-medicate to relieve the symptoms of PTSD. Consequently, there is a clear need for standardized, FDA approved, oral cannabis products which can, and should be, provided to veterans and others who can benefit from its use. Medical cannabis has far fewer and milder side effects than most currently prescribed pharmaceutical products do. We are working hard to have one or more products ready for FDA clinical trials as soon as possible.

The completion of a 1,300 participant veteran survey regarding PTSD (Post-Traumatic Stress Disorder) was announced on March 1, 2010. On the survey, veterans reported that cannabis helped with nearly all PTSD symptoms with special emphasis on three important components: sleep disturbance, irritability, and disturbing memories. These findings are significant given that PTSD is notorious for leading to difficulty falling and staying asleep. Responded also reported that aggression and disturbing thoughts were also greatly reduced through the use of cannabis. This survey demonstrates an advantage over conventional pharmaceutical research companies that Cannabis Science enjoys. As a patient-oriented company we know that real people with real problems are getting real relief from cannabis. Also, it is important to note that insomnia is a very widespread problem in the general population, especially senior citizens, so the need for cannabis based medicines for sleep is not confined to people with PTSD. In fact, it is a multi-billion dollar a year market.

On March 17, 2011, the Company signed an agreement with The Unconventional Foundation for Autism (UF4A) to develop treatment plans and targeted cannabis-based medicine for the treatment of autism. In conjunction with the partnership, the Company’s president and CEO, Robert Melamede, Ph.D. will join the board of UF4A and work alongside their staff to document and provide scientific guidance on the 10 autism treatment with medical marijuana case studies that UF4A is currently involved with.

The Company anticipates having to raise additional capital to fund operations over the next 12 months. To the extent that it is required to raise additional funds to acquire properties, and to cover costs of operations, the Company intends to do so through additional public or private offerings of debt or equity securities.

FEATURED Splash Beverage Group Reports Record First Quarter 2022 Financial Results. Revenues Increase 86% Year over Year with $4 Million in Gross Sales as Company Signs 12 New or Expanded Distribution Agreements May 16, 2022 8:02 AM

OTC: ILUS, ILUS International (Ilustrato Pictures International Inc) Summarizes Its First Quarter of 2022 Disclosure ILUS May 16, 2022 4:00 PM


Integrated Ventures Reports Q3/2022 Financial Results With Total Revenues Of $1,431,819 And Gross Profit Of $307,492.00. INTV May 16, 2022 9:00 AM

RENAVOTIO, INC. (RIII) Provides Shareholder updates RIII May 13, 2022 3:38 PM

Demand Brands and Truleaf discussing the future of DB's retail footprint DMAN May 13, 2022 3:11 PM

OMID Posts First-Quarter 2022 Financial Statements OMID May 13, 2022 10:00 AM

"VAPR" E-Cite Motors Profiled as AMAZING EV Auto Investment in EV Auto Insider - Above GOOD Tesla, and Those Making its' TERRIBLE Investment List VAPR May 13, 2022 9:49 AM

American Green, Inc. ™ (OTC:ERBB) Board Votes to Exercise its Option to Buy 40,000 square foot "Cypress Chill" Cannabis Building for $3,750,000 ERBB May 13, 2022 8:30 AM

Progressive Care to Report First Quarter Financial Results on May 17, 2022 RXMD May 13, 2022 8:06 AM

Alliance Creative Group (ACGX) Reports Revenue of $2,865,404 for First Quarter of 2022 ACGX May 13, 2022 8:00 AM

Commerce Resources Produces Additional Mixed REC Sample with 22.4% NdPr from the Ashram Deposit, Quebec CCE May 13, 2022 7:30 AM

Demand Brands CEO Letter to Shareholders and The Year Ahead DMAN May 12, 2022 11:32 AM

Branded Legacy, Inc. Adds Multiple New Accounts BLEG May 12, 2022 11:06 AM

Mawson Infrastructure Group Inc. Announces April 2022 Bitcoin Self-Mining, Hosting Co-location and Operational Update MIGI May 12, 2022 9:12 AM